🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Time is running out to get the best registration rates for #AMPATH24, the AMP 2024 Annual Meeting & Expo! Register by September 20th to save big and join us in Vancouver, BC, Canada this November 19-23rd! Register here: ow.ly/nta650ToyZc

KRAS G12C mutations occur in approximately 3-4% of CRCs and are predictive of response to combo EGFR and KRAS G12C inhibition. To characterize unique features of G12C-mutant CRC, we analyzed 1347 CRCs in the Harvard NHS/HPFS cohorts. Read more: onlinelibrary.wiley.com/doi/10.1111/ca…

Super resource for expert advice on numerous leading-edge image analysis tools. Thanks Shatavisha.

Thanks for highlighting our lab’s classic KRAS assay The Journal of Molecular Diagnostics! Served us well for more than a decade. Pyrosequncing traces were always such fun little puzzles. Might be dating myself, but we were still running this assay when I was an MGP fellow.

Thank you, Alliance for Clinical Trials in Oncology, for the recognition of our team. Large multi site trials like C80702 provide such a wealth of high impact data for patient care. Look for our ctDNA results coming early next year!

Wolpin-Nowak lab entry into the Dana-Farber pumpkin decorating contest. We started with an mIF image of the PDAC TME then used AI to render as a skull with a Dia de Los Muertos theme. Hand painted by the amazing Bridget Cahill of the Rosenthal lab. Happy Friday everyone!

Great start to the Break Through Cancer 2024 summit hosted by MD Anderson Cancer Center in Houston! Looking forward to the next two days. #RadicalCollaboration

🌟 Let's support our #AMPath24 Host City! 🌟 This year, AMP will contribute a $5,000 charitable donation to the PHS Community Services Society which aids under-served people in Vancouver and Victoria. 🤝 Learn more at ow.ly/y3Mf50U6yXA

Thrilled to kick off the 30th annual AMP annual meeting in Vancouver earlier this morning! Thanks to our Program Committee members and AMP staff for putting together a great agenda for us.

Happening now at the AMP annual meeting: Professional Relations Committee addressing AMP’s lawsuit against the FDA challenging oversight of LDT procedures. Very grateful for the deep expertise on this panel. Association for Molecular Pathology #AMPath24

New to Association for Molecular Pathology and want to get involved? The Membership Affairs Committee has prepared this excellent visual guide for you! According to this, I like people sometimes, and planning, but not money. Also like big events. #AMPath24

How can tumor-derived evidence improve classification of germline variants in cancer patients? The INT2GRATE consortium showcases a solution. Presented by Brigham and Women's Pathology Arezou Ghazani at #AMPath24 genetics selected abstracts session. Association for Molecular Pathology

Standing room only for Columbia Pathology Dr. Susan Hsiao presenting on clinical cancer exome sequencing and transcriptome profiling for pediatric patients at #AMPath24. Amazing that her lab has been doing this work for nearly a decade. Association for Molecular Pathology

Amazing input requirements and performance characteristics for internally developed clinical WES at Dartmouth Hitchcock Medical Center and Clinics pathology. Laura J. Tafe, MD at #AMPath24. Association for Molecular Pathology

Thought provoking Solid Tumor plenary session at #AMPath24 by Peter Sorger Harvard Medical School on insights gained from and opportunities presented by spatial tissue profiling and ML. Also so many beautiful images. Association for Molecular Pathology

So many opportunities to learn from long range sequencing approaches. Great perspective on the current landscape and personal experience presented by Fritz Sedlazeck BCM HGSC at #AMPath24. Association for Molecular Pathology

NCT06445062: Revolution Medicines trial combining RMC-6236 with either FOLFIRINOX or Gemcitabine/nab-paclitaxel in treatment naive #PancreaticCancer. This study is now open at 17 locations nationwide. Also includes sub-cohorts for #ColorectalCancer and 2nd line pancreatic cancer.

Thrilled for the Wolpin-Nowak lab to be part of the correlative science team for this cohort! An amazing opportunity to conduct great science using human specimens to rapidly improve RAS inhibitor use in PDAC.

Excited to head to ASCO GI next week to present our work on the prognostic and predictive role of ctDNA in stage III colon cancer in the 80702 clinical trial. Thanks to ASCO for kindly considering our late-breaking abstract. Alliance for Clinical Trials in Oncology Dana-Farber Natera Oncology #GI25